Norprexanil

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Norprexanil

Quick Facts

Property Description
Active Ingredients Perindopril and Amlodipine
Form Oral Tablet
Pharmacological Class Antihypertensive agents (ACE Inhibitor/CCB Combination)
Common Use Management of high blood pressure (Hypertension)
Origin Synthetic Compound

Norprexanil: What Type of Medicine is It?

Norprexanil is a specific synthetic, prescription-only medicine designed as an antihypertensive agent for the long-term management of high blood pressure (essential hypertension). It is clinically recognized as a Fixed-Dose Combination (FDC) product, delivered as a single oral tablet, a formulation often preferred in clinical practice to enhance patient adherence to therapy. This approach, combining two established compounds, provides a more efficient starting point for adult patients whose condition requires a robust, dual-acting intervention.


Composition and Pharmacological Class (Amlodipine and Perindopril)

Norprexanil is uniquely composed of two primary active ingredients, Perindopril and Amlodipine, each belonging to a distinct, medically verified pharmacological class of cardiovascular drugs. Perindopril is an Angiotensin-Converting Enzyme (ACE) inhibitor, while Amlodipine is a dihydropyridine Calcium Channel Blocker (CCB). This pairing provides comprehensive blood pressure reduction by affecting two independent pathways in the body. This strategic pairing provides a single-tablet solution that is chemically distinct from taking the two components separately.


General Purpose and Effect on Blood Pressure

The general purpose of Norprexanil is to achieve a clinically sustained blood pressure reduction through complementary physiological actions. The combined therapeutic effect systematically lowers peripheral vascular resistance by simultaneously reducing the formation of a natural vasoconstrictor (via Perindopril) and directly relaxing and widening arterial walls (via Amlodipine). This effective control of hypertension is vital for mitigating the long-term risk of severe cardiovascular events in adult patients.

Regulatory References

  1. Hypertensive Heart Disease (NIH StatPearls)

What side effects are possible with Norprexanil?

Possible Side Effects and Safety Information

The safety profile for Norprexanil (Perindopril/Amlodipine) is defined by officially documented adverse reactions classified by frequency and affected body system, strictly according to regulatory standards from government health authorities. Adverse reactions are grouped across six formal frequency tiers.

Frequency-Classified Adverse Reactions

Frequency Tier Examples of Documented Adverse Reactions
Very Common (ge 1/10) Ankle swelling (Oedema)
Common (ge 1/100 to < 1/10) Dizziness, Headache, Cough, Fatigue, Abdominal pain, Nausea, Muscle spasms
Uncommon (ge 1/1,000 to < 1/100) Hypotension, Syncope, Vertigo, Rash, Angioedema

System-Organ Classes and Serious Reactions

Side effects are formally grouped by the System-Organ-Class affected, including Vascular disorders (e.g., Hypotension), Nervous system disorders (e.g., Dizziness), and Gastrointestinal disorders. The regulatory documents explicitly list Serious Adverse Reactions (SARs), which are rare but clinically significant.

Key SARs documented include Angioedema (swelling of the face, tongue, or larynx), Severe Hypotension, and rare instances of Hepatitis or Toxic Epidermal Necrolysis.


Population-Specific Safety Constraints

The official labeling includes specific restrictions for certain populations. The medicine is contraindicated during the second and third trimesters of pregnancy. Use is also formally contraindicated in patients with a history of Angioedema related to previous ACE inhibitor therapy and in those with severe hepatic impairment or clinically significant aortic stenosis. Furthermore, Hypotension and related symptoms are noted to be more likely to occur after the first dose or when the dose is increased.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Norprexanil is officially documented to result primarily in profound hemodynamic instability, a condition characterized by marked and prolonged systemic hypotension (severe low blood pressure) and excessive peripheral vasodilatation. Documented clinical manifestations may also include reflex tachycardia or bradycardia, dizziness, fainting, and signs of electrolyte disturbances. The most severe outcomes listed in regulatory documents include circulatory shock, which has been associated with fatal consequences, acute renal failure, and cardiovascular events such as myocardial infarction or stroke.

When to Seek Immediate Medical Attention

The official prescribing information explicitly mandates that immediate medical attention must be sought upon any suspicion of overdose. Emergency services should be contacted if the affected individual exhibits severe signs such as collapse, difficulty breathing, seizure activity, or any manifestation of circulatory shock. Due to the long half-life of Amlodipine, extended hospital observation and continuous monitoring of vital signs are required in a specialized unit.

Official Management and Treatment

Management focuses on supportive and symptomatic treatment. Procedural measures documented include gastric lavage or the administration of activated charcoal within the first hours of ingestion. While no specific antidote is known for the combination, procedures like calcium gluconate infusion are described to counteract the calcium channel blocker effects. Interventions such as intravenous fluids and vasopressors are listed for managing severe hypotension, and the Perindopril component is documented as being dialyzable.

Therapeutic Uses of Norprexanil

What Norprexanil Treats: Main Uses and Benefits

Norprexanil is generally indicated for the long-term management of chronic cardiovascular conditions, focusing on systemic, silent risks rather than acute symptomatic relief. Its core therapeutic use is managing Hypertension.

This combination medication is used for managing conditions characterized by persistently elevated blood pressure readings and is relevant for adult patients with a high cardiovascular risk profile, including those with co-existing Stable Coronary Artery Disease. This therapeutic approach helps address the underlying condition by providing support that may help in lowering the risk of severe complications, including stroke and myocardial infarction (heart attack).

The fixed-dose combination strategy is often applied during phases when blood pressure has proven uncontrolled despite previous attempts with single-drug therapy. By contributing to sustained blood pressure reduction, the medication may assist in supporting functional stability and supports patients with symptom clusters that create noticeable physiological strain.

Quick Fact: Relief for Vascular Stress
This medication is applied in situations involving elevated blood pressure, where it is applied to help ease the overall systemic stress on arteries and the heart.

Eligibility and Restrictions for Use

Official Eligibility Profile

Norprexanil (Perindopril and Amlodipine) is approved for use in adult patients (18 years and older) for the treatment of essential hypertension. Official regulatory documents strictly define the populations for whom use is prohibited or restricted.

Category Official Regulatory Classification
Populations Contraindicated Patients with a history of angioedema related to any ACE inhibitor, or hypersensitivity to either active ingredient. Contraindicated in specific structural heart conditions and when used concomitantly with sacubitril/valsartan.
Reproductive Status Contraindicated during the 2^ nd and 3^ rd trimesters of pregnancy. Use is not recommended while breastfeeding.
Age Restriction Pediatric patients (under 18 years): Safety and efficacy have not been established.
Organ Impairment Not recommended for use in patients with hepatic impairment or with severe renal impairment (CrCL < 60 mL/min).

The eligibility profile is structured by Absolute Contraindications, prohibiting use in specific allergic reactions or in combination with certain drugs like aliskiren in diabetic patients. Exclusionary rules limit use in defined patient groups, most notably for organ impairment and pregnancy status, where use is formally prohibited.

What should I know about interactions with other medicines?

Norprexanil (Perindopril/Amlodipine) is subject to specific regulatory restrictions and requires caution with several medicinal products and substances. These documented interaction patterns reflect both pharmacodynamic and pharmacokinetic mechanisms.

Absolute Regulatory Prohibitions and Restrictions

  • Sacubitril/Valsartan is strictly contraindicated due to an increased risk of angioedema. A mandatory 36-hour separation period is required before initiating or stopping this combination.
  • Aliskiren is contraindicated in patients with diabetes mellitus or moderate to severe renal impairment, reflecting restrictions on dual RAAS blockade.
  • Specific extracorporeal treatments (e.g., certain dialysis or apheresis procedures) are prohibited due to the risk of severe systemic reactions documented with the ACE inhibitor component.

Exposure and Pharmacodynamic Interactions

  • Potassium-Sparing Agents and Supplements: Concomitant use increases the risk of Hyperkalemia due to the pharmacodynamic effect of the Perindopril component.
  • CYP3A4 Inhibitors (e.g., Ketoconazole) may increase the systemic exposure of Amlodipine, while inducers may decrease exposure.
  • The dose of Simvastatin must not exceed 20 mg daily when co-administered, a restriction necessitated by Amlodipine’s effect on Simvastatin exposure.
  • NSAIDs may lead to a reduction in the antihypertensive effect and deterioration of renal function. Grapefruit or grapefruit juice consumption may increase Amlodipine exposure.

Mechanism of Action

Norprexanil exerts its effects through the precise modulation of distinct signaling pathways, engaging mechanisms that influence processes characterized by heightened mediator activity. It operates across multiple mechanistic domains that result in altered circulating levels of key vasoactive peptides and associated downstream receptor engagement.


Enzyme-Mediated Signal Inhibition

This domain focuses on the drug's capacity to initiate or suppress signaling sequences, resulting in modification of molecular steps along the cascade. Norprexanil modifies early molecular steps, specifically by competitively inhibiting a key enzyme, which prevents the rapid conversion of an inactive precursor molecule (Angiotensin I) into a vasoactive peptide (Angiotensin II). This targeted effect affects cascades where multiple layers of pathway activation occur.


Pathway Modulation for Vascular Regulation

The drug acts within domains involving receptor-mediated signaling associated with heightened physiological responses in the cardiovascular system. By reducing the overall availability of the vasoactive mediator (Angiotensin II), the drug ultimately reduces the stimulation of its receptors on vascular smooth muscle. This results in decreased basal vascular tone and reduced downstream signaling events within the targeted pathways.


Kinase II Activity and Endogenous Vasodilation

Norprexanil also engages mechanisms that influence feedback regulation within related pathways. The same enzyme it inhibits (Angiotensin-Converting Enzyme, or ACE, also known as Kinase II) is also responsible for deactivating bradykinin, a naturally occurring peptide that acts as a strong vasodilator. Its action, therefore, also results in increased bioavailability of bradykinin and an associated downstream effect of vascular smooth muscle relaxation.

Dosage and Administration Information

How to Use Norprexanil

Norprexanil (Perindopril and Amlodipine) is administered as an oral tablet once daily for the long-term management of chronic hypertension. The administration protocol is defined by specific guidelines regarding its schedule, dosage, and adjustment procedures.

Administration Schedule and Dosing

The medication is taken as a single dose once daily. It is often recommended to take the tablet in the morning before a meal to standardize intake, though it may also be taken with or without food.

Treatment follows a titration-based approach, often starting with a low initial dose, such as 3.5 mg Perindopril / 2.5 mg Amlodipine. The maximum recommended daily dose is 14 mg Perindopril / 10 mg Amlodipine. The dose adjustment process is procedural: any dose change should only occur after 7 to 14 days at the current strength, allowing the full effect to be established before the next step.

Procedural Constraints and Special Usage

Usage is generally not established for children and adolescents. Specific population-based constraints are defined for patients with impaired kidney function; in these cases, the dose may be restricted (e.g., capped at 7 mg / 5 mg) or use may be not recommended if the creatinine clearance is below 60 mL/min. In the event of a missed dose, the instruction is to not double the dose to compensate; the regular single-dose schedule must be resumed at the next planned time.

Recent Clinical Evidence

Research evidence / Overview of studies for Norprexanil

Evidence for Use in High Blood Pressure (Hypertension)

Norprexanil, a medication containing two active substances, was studied to explore its effect on high blood pressure, a condition characterized by functional limitations. Research examined how this combination was observed to affect blood pressure levels compared to receiving an inactive treatment or using the two medications separately. These studies primarily focused on outcomes related to systemic or functional imbalance across various patient groups.

Clinical trials involving thousands of participants report how symptoms evolved in the observed populations, primarily showing patterns related to changes in blood pressure readings. These findings describe patterns observed in the studies over defined time intervals, contributing to understanding symptom patterns.


Evidence for Use in Coronary Artery Disease (CAD)

Research examined Norprexanil’s role in people who have stable coronary artery disease and also have high blood pressure. This evidence was evaluated in studies focusing on outcomes related to heart health and the circulatory system over defined time intervals. The evidence contributes to the broader evidence landscape by describing certain changes measured during the study period in this patient group.


Long-term Studies and Follow-up

The long-term outcomes of using Norprexanil were observed in research exploring its sustained effects on high blood pressure and heart health. Research examined how the medication affects patients over multiple years, particularly concerning the durability of the blood pressure response and overall stability in conditions characterized by fluctuating or episodic manifestations. Data are still emerging regarding very long-term outcomes, and there is limited information for long-term outcomes in patients who deviate significantly from the typical trial participant, meaning certainty remains low for the entire population.


Evidence in Special Populations

Studies were evaluated in various special populations, including older adults and those with co-existing health issues, such as chronic kidney or liver considerations. Research describes findings within specific ranges of the medication and the patient populations studied in older adults. Data for certain groups remain insufficient. Specifically, for children and pregnancy-related populations, evidence is limited due to a lack of dedicated studies.


What Is Still Uncertain About Norprexanil

This section synthesizes the areas where knowledge remains incomplete. The compilation of findings indicates that evidence quality varies across studies due to differences in design and scope, and subgroup findings are uncertain when trying to apply results to small patient groups. Major gaps include a deeper understanding of very long-term outcomes, certainty regarding outcomes in specific less-studied subgroups, and comparative evidence is lacking for certain head-to-head comparisons. The evidence highlights what is known — and what is still uncertain regarding the full breadth of Norprexanil’s effects in the general population.

Frequently Asked Questions (FAQ)

Common questions about Norprexanil (FAQ)


Q: How quickly does Norprexanil start working after the first time taking it?

A: According to official product information, the component responsible for lowering blood pressure typically reaches its maximum effect within 4 to 6 hours after taking a single dose. While some initial effect begins quickly, the full therapeutic benefit is generally established over a period of 7 to 14 days as treatment continues.


Q: Is Norprexanil safe to take for a long period of time?

A: Norprexanil is indicated for the long-term management of chronic conditions like high blood pressure and stable coronary artery disease. Studies have been conducted to observe the sustained effects over multiple years. Regulatory labeling indicates that long-term use requires periodic patient monitoring.


Q: Does Norprexanil cause weight gain or weight loss?

A: Official documentation does not list general weight changes as common side effects; however, reports of unusual weight gain or swelling (oedema) have been noted in some patient experiences. Patients who experience unexpected changes in weight or swelling are advised to consult their healthcare provider for evaluation.


Q: Does Norprexanil interact with cold and flu medications?

A: Regulatory information describes potential interactions with medicines containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are common in cold and flu products. NSAIDs may reduce the expected blood pressure-lowering effect and could potentially affect kidney function.


Q: Are there any foods or drinks I should avoid while on Norprexanil?

A: Yes, official product information states that grapefruit or grapefruit juice should be avoided. Consuming these products may increase the systemic exposure of the Amlodipine component in the body, potentially leading to increased side effects.


Q: What is the risk of stopping Norprexanil suddenly?

A: The decision to discontinue any blood pressure medication must be made by a qualified healthcare professional. Official safety information notes that abrupt cessation of the Amlodipine component is associated with a risk of increased angina or myocardial infarction, particularly in specific patient populations.


Q: Does Norprexanil affect the ability to drive or operate machinery?

A: Official labeling states that caution should be exercised regarding driving or operating machinery. Side effects such as dizziness, fatigue, or fainting (syncope) are documented and may affect concentration or coordination. It is generally advised that individuals observe how the medication affects them before undertaking potentially risky activities.


Q: Can I take Norprexanil if I have an existing heart condition?

A: Norprexanil is indicated for stable coronary artery disease and hypertension. However, it is contraindicated (officially prohibited) in patients with specific severe heart conditions, such as aortic stenosis or cardiogenic shock. The final determination regarding eligibility is based on a patient’s comprehensive medical assessment.


Q: What should I do if I experience a mild headache after starting Norprexanil?

A: Headache is listed in official documentation as a Common side effect, meaning it is reported in up to 1 in 10 patients. This is a potential effect of the treatment. Any concerning or persistent side effects, including headache, should be communicated to a healthcare professional.


Q: Does alcohol interact with Norprexanil?

A: Official information indicates that alcohol may increase the blood pressure-lowering effect of Norprexanil. This increased effect can raise the risk of experiencing side effects such as dizziness, lightheadedness, or fainting.


Q: Why is Norprexanil sometimes called a 'selective' medication?

A: The Perindopril component works by selectively blocking a specific substance in the body called the Angiotensin-Converting Enzyme (ACE). This targeted action interrupts the process that narrows blood vessels, thereby helping to lower blood pressure.


Q: If I am allergic to other medicines, can I still take Norprexanil?

A: Official eligibility documents state that this medication is contraindicated if a patient is allergic to either active ingredient (Perindopril or Amlodipine) or to other medicines in the same classes, such as any other ACE inhibitor or dihydropyridine derivative. These specific allergies are exclusionary.


Q: What does the term 'contraindication' mean for Norprexanil?

A: A contraindication is a condition or circumstance that, according to regulatory standards, officially prohibits the use of the drug. The official list of contraindications highlights situations where the risk of using the medicine is greater than the potential benefit, such as during the second and third trimesters of pregnancy.


Q: Can Norprexanil cause changes in mood or sleep patterns?

A: Official adverse reaction reports include changes in mood and sleep patterns. Examples reported include insomnia (difficulty sleeping) and, in some cases, mood alterations (e.g., nervousness, anxiety). These are typically reported as uncommon side effects.


Q: Why are routine blood tests sometimes required when taking Norprexanil?

A: Routine blood and urine tests are often performed to monitor for potential changes in body levels, especially serum potassium and creatinine (a measure of kidney function). This is because the medication can sometimes cause shifts in the levels of these substances in the blood.


Q: Does Norprexanil affect hormone levels?

A: The Perindopril component works by interrupting the Renin-Angiotensin System, which is a complex pathway that regulates blood pressure. This system involves the control of hormones like aldosterone that manage fluid balance in the body.


Q: Are there different versions or generics of Norprexanil available?

A: Norprexanil is a brand name for the fixed-dose combination of the active ingredients Perindopril and Amlodipine. Due to regulatory approvals, this combination is also available under various other brand names and may be available as authorized generic versions, depending on the country.


Q: How long does Norprexanil stay in the body after the last dose?

A: Pharmacokinetic data shows that the components leave the body at different rates. The active part derived from Perindopril typically has a shorter half-life of a few hours, while the Amlodipine component has a longer half-life, ranging from 30 to 50 hours.


Q: Is Norprexanil intended to cure a condition or just manage symptoms?

A: The medication is indicated for the management (treatment) of essential hypertension and stable coronary artery disease. Like most medicines for these chronic illnesses, it is intended to help control the condition and reduce risks, but it is not considered a cure.


Q: Can I take Norprexanil if I am taking birth control pills?

A: The official documentation does not indicate a specific or problematic interaction between Norprexanil and common oral contraceptives. However, the label does list specific hormonal interactions with other types of related drugs. Official safety documents recommend that patients review all concurrent medications with their healthcare provider.


Q: Does Norprexanil have a 'Black Box Warning' according to the FDA?

A: Yes, the FDA label includes a Boxed Warning regarding Fetal Toxicity. This warning states that drugs like Norprexanil that act directly on the renin-angiotensin system can cause injury and death to a developing fetus. The Boxed Warning stipulates that the drug should be discontinued as soon as possible if pregnancy is detected, due to the risk of fetal harm.


How should Norprexanil be stored and disposed of?

Norprexanil (perindopril/amlodipine) must be stored strictly according to governmental labeling to ensure the stability of the tablets.

Official Storage Conditions

Condition Regulatory Requirement
Temperature Store at room temperature, typically between 20 C to 25 C, and keep from freezing.
Protection Must be protected from light and moisture and stored away from excess heat.
Packaging Keep the tablets in their original package (container or blister) and in a tightly closed container where applicable.
Child Safety Mandatory instruction to keep out of the reach of children and out of sight.

Disposal Requirements

Expired or unused Norprexanil should not be thrown into household trash or poured into wastewater. Disposal must be conducted as instructed by a healthcare professional or pharmacist, following local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Norprexanil found in:

A-Z Index: